Autolus Therapeutics plc

DB:6A3A Stock Report

Market Cap: €317.4m

Autolus Therapeutics Valuation

Is 6A3A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6A3A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€32.41
Fair Value
96.4% undervalued intrinsic discount
9
Number of Analysts

Below Fair Value: 6A3A (€1.17) is trading below our estimate of fair value (€32.41)

Significantly Below Fair Value: 6A3A is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6A3A?

Key metric: As 6A3A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6A3A. This is calculated by dividing 6A3A's market cap by their current revenue.
What is 6A3A's PS Ratio?
PS Ratio35x
SalesUS$10.12m
Market CapUS$359.27m

Price to Sales Ratio vs Peers

How does 6A3A's PS Ratio compare to its peers?

The above table shows the PS ratio for 6A3A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.7x
FYB Formycon
5.9x18.4%€410.5m
BIO3 Biotest
1.6xn/a€1.4b
2INV 2invest
2.7xn/a€68.9m
HPHA Heidelberg Pharma
20.5x39.7%€140.7m
6A3A Autolus Therapeutics
35x48.2%€359.3m

Price-To-Sales vs Peers: 6A3A is expensive based on its Price-To-Sales Ratio (35x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does 6A3A's PS Ratio compare vs other companies in the DE Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.6xn/aUS$1.62b
2INV 2invest
2.7xn/aUS$78.02m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
6A3A 35.0xIndustry Avg. 7.8xNo. of Companies9PS01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6A3A is expensive based on its Price-To-Sales Ratio (35x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is 6A3A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6A3A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6A3A's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6A3A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.17
€8.76
+649.0%
24.7%€12.25€5.25n/a9
Apr ’26€1.41
€9.34
+562.1%
23.2%€12.94€5.55n/a9
Mar ’26€1.66
€10.12
+509.8%
18.9%€13.34€7.24n/a9
Feb ’26€2.12
€10.20
+381.2%
16.3%€12.62€7.38n/a9
Jan ’26€2.14
€10.03
+368.5%
17.3%€12.27€7.17n/a9
Dec ’25€3.22
€10.03
+211.3%
17.3%€12.27€7.17n/a9
Nov ’25€3.06
€9.11
+197.7%
18.0%€11.84€6.38n/a8
Oct ’25€3.22
€9.17
+184.6%
17.7%€11.66€6.28n/a9
Sep ’25€3.54
€9.17
+158.9%
17.7%€11.66€6.28n/a9
Aug ’25€4.30
€9.71
+125.9%
23.4%€14.74€6.36n/a9
Jul ’25€3.20
€9.71
+203.5%
23.4%€14.74€6.36n/a9
Jun ’25€3.64
€9.71
+166.8%
23.4%€14.74€6.36n/a9
May ’25€3.60
€9.71
+169.8%
23.4%€14.74€6.36€1.139
Apr ’25€5.70
€9.28
+62.8%
17.9%€11.94€6.34€1.419
Mar ’25€5.45
€9.21
+69.0%
19.8%€12.07€5.85€1.669
Feb ’25€5.50
€9.02
+64.0%
24.5%€11.99€4.61€2.129
Jan ’25€5.90
€8.31
+40.9%
28.8%€11.12€4.45€2.148
Dec ’24€3.68
€8.06
+119.0%
33.5%€11.02€2.94€3.228
Nov ’24€2.58
€7.93
+207.4%
36.5%€11.33€2.64€3.067
Oct ’24€2.22
€7.55
+240.1%
38.7%€11.36€2.65€3.228
Sep ’24€2.88
€7.03
+144.1%
39.9%€11.04€2.58€3.549
Aug ’24€2.84
€6.84
+140.8%
41.7%€11.22€2.62€4.309
Jul ’24€2.18
€6.84
+213.7%
41.7%€11.22€2.62€3.209
Jun ’24€2.80
€6.81
+143.0%
42.0%€11.19€2.52€3.649
May ’24€1.62
€6.68
+312.5%
39.9%€11.12€2.50€3.608
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
€8.81
Fair Value
86.7% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 11:26
End of Day Share Price 2025/05/05 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Autolus Therapeutics plc is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingrid GafanhãoBryan Garnier & Co
Rajan SharmaGoldman Sachs
Biren AminJefferies LLC